Gilead Sciences (1GILD) Price & Analysis
1GILD Stock Chart & Stats
- Day’s Range
- EUR 153.06 - EUR 155.58
- 52-Week Range
- EUR 53.00 - EUR 188.00
- Previous Close
- EUR 144.70
- Volume
- 0
- Average Volume (3M)
- 116
- Market Cap
- EUR 188.86B
- Enterprise Value
- EUR 204.66B
- Total Cash (Recent Filing)
- EUR 6.44B
- Total Debt (Recent Filing)
- EUR 26.23B
- Price to Earnings (P/E)
- ―
- Beta
- 0.06
- Next Earnings
- Feb 04, 2027
- EPS Estimate
- 1.24
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.81%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Exceptionally strong operating and free cash flow provides financial resilience even when reported earnings are weak. This supports continued investment in research and development, funding for launches, debt servicing, and shareholder returns without relying solely on external financing.
HIV Franchise Momentum
The HIV franchise combines recurring chronic-treatment demand with strong product adoption and market leadership. Growth in Biktarvy, prevention products, and newer options such as Yeztugo gives Gilead a durable commercial base and supports continued cash generation.
Pipeline Diversification
A broad pipeline across several therapeutic areas can reduce dependence on any single product or franchise over time. Continued development in oncology and inflammation, alongside multiple long-acting HIV programs, improves the company’s prospects for renewing growth.
Bears Say
Biktarvy Pricing Pressure
The planned CMS price reduction creates a material, identifiable pressure on Gilead’s largest HIV product and may also affect other U.S. payer channels. Replacing that revenue will require sustained growth from newer HIV products and other therapeutic areas.
Cell Therapy Contraction
Declining cell therapy sales indicate that competitive pressure is currently outweighing portfolio growth in this strategic area. Continued weakness could reduce oncology contribution, limit operating leverage, and make the broader diversification strategy more dependent on successful launches.
Volatile Reported Profitability
The swing from strong prior-year profitability to a TTM operating loss shows that reported earnings remain highly volatile. This weakens confidence in near-term earnings quality and reduces the reliability of accounting profits as a measure of ongoing business performance.
1GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
What is Gilead Sciences’s market cap?
When is Gilead Sciences’s upcoming earnings report date?
How were Gilead Sciences’s earnings last quarter?
Is Gilead Sciences overvalued?
Does Gilead Sciences pay dividends?
What is Gilead Sciences’s EPS estimate?
How many shares outstanding does Gilead Sciences have?
What happened to Gilead Sciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Gilead Sciences?
What is the TipRanks Smart Score and how is it calculated?
Gilead Sciences Stock Smart Score
Company Description
Gilead Sciences
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day
- Employees
- 17,000
- Website
- www.gilead.com
- Address
- 333 Lakeside Drive, Foster City, CA, 94404, US
Gilead Sciences (1GILD) Earnings & Revenues
1GILD Company Deck
1GILD Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Gilead reported its strongest base business growth in more than a decade, broad-based product momentum, improved margins, raised revenue and adjusted EPS guidance, significant pipeline progress, and continued diversification across HIV, oncology, inflammation, and cell therapy. These positives outweighed the stated challenges, including the projected $1.5 billion 2028 Biktarvy revenue impact from CMS pricing, cell therapy declines, clinical holds, lower Veklury and HCV sales, and acquisition-related charges.
View all IT:1GILD earnings summaries1GILD Net sales Breakdown
- 70.48% HIV
- 10.93% Liver Disease
- 3.09% Veklury
- 10.99% Oncology
- 2.71% Other
- 1.79% Royalty, contract and other revenues
1GILD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |